AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29297555 — intervention group
Group type: COMPARATOR
Intervention: Control group subjected to 1 erosive/abrasive cycle (C1)
Number of subjects: 72
Study 29297555 — intervention group
Group type: COMPARATOR
Intervention: Control group subjected to 2 erosive/abrasive cycles (C2)
Number of subjects: 72
Study 29297555 — intervention group
Group type: COMPARATOR
Intervention: Control group subjected to 3 erosive/abrasive cycles (C3)
Number of subjects: 72
Study 29297555 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro uneroded samples (UN) subjected to 3 erosive/abrasive cycles
Number of subjects: 72
Study 25929594 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 12.5 mg once daily
Number of subjects: 0
Study 25929594 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 25 mg once daily
Number of subjects: 0
Study 25929594 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 50 mg once daily
Number of subjects: 0
Study 25929594 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 75 mg once daily
Number of subjects: 0
Study 25929594 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-titration regimen
Number of subjects: 0
Study 25929594 — intervention group
Group type: COMPARATOR
Intervention: Fixed doses of eltrombopag (12.5, 25, 50, 75 mg once daily)
Number of subjects: 0
Study 23259702 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-teriparatide group (after 72 weeks of teriparatide injections)
Number of subjects: 465
Study 23259702 — intervention group
Group type: COMPARATOR
Intervention: Post-placebo group (after 72 weeks of placebo injections)
Number of subjects: 465
Study 23259702 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates treatment after teriparatide
Number of subjects: 465
Study 22256222 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) over the left primary motor cortex (M1)
Number of subjects: 0
Study 22256222 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 19054188 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation (1.7 g DHA and 0.6 g EPA per day)
Number of subjects: 204
Study 19054188 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.6 g linoleic acid per day)
Number of subjects: 204
Study 16702317 — intervention group
Group type: EXPERIMENTAL
Intervention: Carob fiber (0, 5, 10, or 20 g)
Number of subjects: 20
Study 16702317 — intervention group
Group type: EXPERIMENTAL
Intervention: Carob fiber (20 g)
Number of subjects: 20
Study 16702317 — intervention group
Group type: COMPARATOR
Intervention: Control meal
Number of subjects: 20
Study 14962718 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30
Number of subjects: 68
Study 14962718 — intervention group
Group type: COMPARATOR
Intervention: FACIT
Number of subjects: 68
Study 14962718 — intervention group
Group type: EXPERIMENTAL
Intervention: Both questionnaires
Number of subjects: 68
Study 11731509 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid analgesics prescribed on an around-the-clock (ATC) basis
Number of subjects: 65
Study 11731509 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid analgesics prescribed on an as-needed (PRN) basis
Number of subjects: 65
Study 11027118 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconferencing (n = 76)
Number of subjects: 145
Study 11027118 — intervention group
Group type: COMPARATOR
Intervention: Conventional hospital outpatient clinic (n = 69)
Number of subjects: 145
Study 8990406 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase (10 + 10 U double bolus)
Number of subjects: 930
Study 8990406 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase
Number of subjects: 930
Study 1619382 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril (20 mg daily)
Number of subjects: 29
Study 1619382 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50 mg daily)
Number of subjects: 29
Study 6390203 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 187
Study 6390203 — intervention group
Group type: COMPARATOR
Intervention: Medical-regimen
Number of subjects: 187
Study 30634657 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 103
Study 30634657 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 103
Study 30063280 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-loaded mini dental implants
Number of subjects: 30
Study 30063280 — intervention group
Group type: COMPARATOR
Intervention: Immediate-loaded conventional-size dental implants
Number of subjects: 30
Study 30063280 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 26966971 — intervention group
Group type: COMPARATOR
Intervention: 1-level ACDF
Number of subjects: 186
Study 26966971 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-level ACDF
Number of subjects: 186
Study 26966971 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 186
Study 24974075 — intervention group
Group type: COMPARATOR
Intervention: Prophylaxis (ondansetron 8mg at cord clamping)
Number of subjects: 82
Study 24974075 — intervention group
Group type: COMPARATOR
Intervention: Treatment (ondansetron 8mg as required)
Number of subjects: 82
Study 24974075 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline 4mL in both)
Number of subjects: 82
Study 21843948 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopex(®) group (40 sides)
Number of subjects: 40
Study 21843948 — intervention group
Group type: COMPARATOR
Intervention: Control group (40 sides)
Number of subjects: 40
Study 19962227 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix 240 mg for 1 month, then 80 mg monthly
Number of subjects: 610
Study 19962227 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide 7.5 mg/month
Number of subjects: 610
Study 17433027 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose lenograstim (263 microg/d)
Number of subjects: 61
Study 17433027 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose lenograstim (105 microg/d)
Number of subjects: 61
Study 17433027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 16290957 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation (CR) - 6 weeks of intensive CR and 12 months of follow-up including patient education, exercise training, dietary counseling, smoking cessation, psychosocial support, risk factor management, and clinical assessment.
Number of subjects: 770
Study 16290957 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 770
Study 12079295 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenretinide
Number of subjects: 16
Study 12079295 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 16
Study 9805346 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (325 mg on alternate days)
Number of subjects: 20979
Study 9805346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20979
Study 7624987 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 400 mg of ofloxacin
Number of subjects: 360
Study 7624987 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 360
Study 2239769 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triglyceride (MCT) diet
Number of subjects: 0
Study 2239769 — intervention group
Group type: COMPARATOR
Intervention: Long-chain triglyceride (LCT) diet
Number of subjects: 0
Study 31511052 — intervention group
Group type: EXPERIMENTAL
Intervention: Dangling protocol
Number of subjects: 0
Study 31511052 — intervention group
Group type: COMPARATOR
Intervention: No-dangling protocol
Number of subjects: 0
Study 27377435 — intervention group
Group type: EXPERIMENTAL
Intervention: Bluetooth hearing aid device A
Number of subjects: 30
Study 27377435 — intervention group
Group type: EXPERIMENTAL
Intervention: Bluetooth hearing aid device B
Number of subjects: 30
Study 27377435 — intervention group
Group type: EXPERIMENTAL
Intervention: Bluetooth hearing aid device A and B
Number of subjects: 30
Study 26289352 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg once daily for 6 months
Number of subjects: 6000
Study 26289352 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo capsules for 6 months
Number of subjects: 6000
Study 23807060 — intervention group
Group type: EXPERIMENTAL
Intervention: Black women Veterans
Number of subjects: 3611
Study 23807060 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic women Veterans
Number of subjects: 3611
Study 23807060 — intervention group
Group type: COMPARATOR
Intervention: White women Veterans
Number of subjects: 3611
Study 21570531 — intervention group
Group type: EXPERIMENTAL
Intervention: Darapladib
Number of subjects: 959
Study 21570531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 959
Study 19420019 — intervention group
Group type: EXPERIMENTAL
Intervention: fosamprenavir/atazanavir/ritonavir (Group 1)
Number of subjects: 61
Study 19420019 — intervention group
Group type: EXPERIMENTAL
Intervention: saquinavir/atazanavir/ritonavir (Group 2)
Number of subjects: 61
Study 16397363 — intervention group
Group type: EXPERIMENTAL
Intervention: ED‐71 (vitamin D analog)
Number of subjects: 0
Study 15075170 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement flued gas or electric heaters
Number of subjects: 198
Study 15075170 — intervention group
Group type: COMPARATOR
Intervention: Control (unflued gas heaters)
Number of subjects: 198
Study 11157685 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin therapy
Number of subjects: 5974
Study 9239449 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual spray of 0.4 mg GTN (two puffs)
Number of subjects: 24
Study 9239449 — intervention group
Group type: COMPARATOR
Intervention: Sublingual tablet of 0.5 mg GTN
Number of subjects: 24
Study 8421980 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (administered to 20 patients: 8 in group 1, 12 in group 2)
Number of subjects: 41
Study 8421980 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (administered to 21 patients: 9 in group 1, 12 in group 2)
Number of subjects: 41
Study 3334056 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg twice daily for 4 weeks
Number of subjects: 0
Study 3334056 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol 200 mg twice daily for 4 weeks
Number of subjects: 0
Study 3334056 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg twice daily and Acebutolol 200 mg twice daily in combination for 4 weeks
Number of subjects: 0
Study 3334056 — intervention group
Group type: COMPARATOR
Intervention: Combination treatment (Nifedipine and Acebutolol)
Number of subjects: 0
Study 29285549 — intervention group
Group type: EXPERIMENTAL
Intervention: Abaloparatide-SC
Number of subjects: 1645
Study 29285549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1645
Study 28558978 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 5mg
Number of subjects: 316
Study 28558978 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 10mg
Number of subjects: 316
Study 28558978 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 316
Study 26607232 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace physical exercise (WORK) performed during working hours for 5x10 min per week and up to 5 group‐based coaching sessions on motivation for regular physical exercise
Number of subjects: 200
Study 26607232 — intervention group
Group type: COMPARATOR
Intervention: Home‐based physical exercise (HOME) performed during leisure time for 5x10 min per week
Number of subjects: 200
Study 24292111 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion axillary lymph node dissection (arm A)
Number of subjects: 2106
Study 24292111 — intervention group
Group type: COMPARATOR
Intervention: Axillary nodal irradiation (arm B)
Number of subjects: 2106
Study 21041839 — intervention group
Group type: EXPERIMENTAL
Intervention: Dianicline
Number of subjects: 602
Study 21041839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 602
Study 18251757 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic treatment (Arnica montana 5 CH, Bryonia alba 5 CH, Hypericum perforatum 5 CH, Ruta graveolens 3 DH)
Number of subjects: 158
Study 18251757 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 158
Study 18251757 — intervention group
Group type: COMPARATOR
Intervention: Open-label noninterventional control arm
Number of subjects: 158
Study 16513246 — intervention group
Group type: EXPERIMENTAL
Intervention: Local estrogen treatment (25-mcg estradiol vaginal tablet or 1g conjugated estrogen cream intravaginally daily for 2 weeks, then twice a week for 10 weeks)
Number of subjects: 53
Study 16513246 — intervention group
Group type: EXPERIMENTAL
Intervention: Local estrogen treatment
Number of subjects: 53
Study 16513246 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hormone replacement therapy)
Number of subjects: 53
Study 16513246 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study 12589396 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg/day)
Number of subjects: 17
Study 12589396 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (100-200 mg/day)
Number of subjects: 17
Study 12589396 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day) in 10 depressed patients
Number of subjects: 17
Study 10826454 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound screening for AAA
Number of subjects: 52745
Study 8854287 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicol gel
Number of subjects: 30
Study 8854287 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 30
Study 1378156 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg once daily
Number of subjects: 20
Study 1378156 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 10 mg t.i.d.
Number of subjects: 20
Study 6692648 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal cefoperazone (CFP)
Number of subjects: 7
Study 6692648 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cefoperazone (CFP)
Number of subjects: 7
Study 28035498 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional CXL (3 mW/cm2 for 30 min)
Number of subjects: 15
Study 28035498 — intervention group
Group type: COMPARATOR
Intervention: Accelerated CXL (9 mW/cm2 for 10 min)
Number of subjects: 15
Study 26771913 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (MPH)
Number of subjects: 112
Study 26771913 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF)
Number of subjects: 112
Study 26771913 — intervention group
Group type: COMPARATOR
Intervention: Physical Activity (PA)
Number of subjects: 112
Study 24795515 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera mouthwash
Number of subjects: 300
Study 24795515 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine gluconate mouthwash
Number of subjects: 300
Study 24795515 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 300
Study 24349414 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus pitch matching using the likeness rating method with pure tones from 0.25 to 16 kHz.
Number of subjects: 0
Study 24349414 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-pitch method for tinnitus pitch matching (0.5 to 20 kHz in 1-Hz steps).
Number of subjects: 0
Study 24349414 — intervention group
Group type: COMPARATOR
Intervention: Assessment of loudness ratings by simulated malingerers.
Number of subjects: 0
Study 24349414 — intervention group
Group type: EXPERIMENTAL
Intervention: Retest data for pitch matching responses.
Number of subjects: 0
Study 24349414 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoacoustic loudness matches.
Number of subjects: 0
Study 20510972 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain Injury Coping Skills Group (12-session, manualized cognitive-behavioral treatment)
Number of subjects: 40
Study 20510972 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain Injury Coping Skills Group
Number of subjects: 40
Study 20510972 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 18492416 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel-epirubicin
Number of subjects: 41
Study 18492416 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil-epirubicin-cyclophosphamide
Number of subjects: 41
Study 16603132 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide (D1/D2 agonist)
Number of subjects: 40
Study 16603132 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine (D2 agonist)
Number of subjects: 40
Study 16603132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12923400 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethaphan 2‐4 mg/min (autonomic blockade)
Number of subjects: 0
Study 12923400 — intervention group
Group type: EXPERIMENTAL
Intervention: LF(SBP)
Number of subjects: 0
Study 11013282 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 5613
Study 9201796 — intervention group
Group type: EXPERIMENTAL
Intervention: Abecarnil 5.0 mg
Number of subjects: 24
Study 9201796 — intervention group
Group type: EXPERIMENTAL
Intervention: Abecarnil 2.5 mg
Number of subjects: 24
Study 9201796 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2.0 mg
Number of subjects: 24
Study 9201796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1443511 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (0.3 mg.kg‐1 bolus followed by 0.06 mg.kg‐1.h‐1 infusion)
Number of subjects: 20
Study 1443511 — intervention group
Group type: COMPARATOR
Intervention: Control (without ketanserin)
Number of subjects: 20
Study 1443511 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 20
Study 3541499 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 26
Study 3541499 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 26
Study 29993224 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 30
Study 29993224 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with nasal irrigation of normal saline (4 times daily) and nasal corticosteroids (one puff in each nostril daily)
Number of subjects: 30
Study 26329584 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute integrity zotarolimus-eluting stents (Medtronic)
Number of subjects: 1811
Study 26329584 — intervention group
Group type: EXPERIMENTAL
Intervention: Promus element everolimus-eluting stents (Boston Scientific)
Number of subjects: 1811
Study 26329584 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifurcated lesions
Number of subjects: 1811
Study 26329584 — intervention group
Group type: COMPARATOR
Intervention: Non-bifurcated lesions
Number of subjects: 1811
Study 26329584 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stent approaches
Number of subjects: 1811
Study 26329584 — intervention group
Group type: COMPARATOR
Intervention: Single-stent approaches
Number of subjects: 1811
Study 25355484 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (2 × 1 g/d)
Number of subjects: 26
Study 25355484 — intervention group
Group type: COMPARATOR
Intervention: Control (soya bean oil, 2 × 1 g/d)
Number of subjects: 26
Study 21915043 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-week computer intervention with nine online self-study health teaching units
Number of subjects: 0
Study 21915043 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 21311484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin treatment (20 ml in 400 ml of 0.9% NaCl solution twice a day intravenously for days 1-10; 850 mg twice a day for days 11-35)
Number of subjects: 70
Study 21311484 — intervention group
Group type: COMPARATOR
Intervention: Control group (basic therapy aimed at improving systemic hemodynamics, rheological blood properties, and prevention of stroke complications)
Number of subjects: 70
Study 17999226 — intervention group
Group type: EXPERIMENTAL
Intervention: Self referent condition
Number of subjects: 211
Study 17999226 — intervention group
Group type: EXPERIMENTAL
Intervention: Spider fearful participants
Number of subjects: 211
Study 17999226 — intervention group
Group type: COMPARATOR
Intervention: Other groups (blood fearful and nonfearful)
Number of subjects: 211
Study 16254521 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG) 4000
Number of subjects: 96
Study 16254521 — intervention group
Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 96
Study 11527057 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisk walking (Sed/Walk)
Number of subjects: 68
Study 11527057 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisk walking (Walk/Walk)
Number of subjects: 68
Study 11527057 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceasing brisk walking (Walk/Sed)
Number of subjects: 68
Study 11527057 — intervention group
Group type: COMPARATOR
Intervention: Sedentary lifestyle (Sed/Sed)
Number of subjects: 68
Study 9032647 — intervention group
Group type: COMPARATOR
Intervention: Polymorphic markers in the GDE gene (‐10G/A, 2001 + 8C/T, 3199C/T)
Number of subjects: 0
Study 8391569 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium fiber (6 gm/day)
Number of subjects: 20
Study 8391569 — intervention group
Group type: COMPARATOR
Intervention: Control cereal (without psyllium fiber)
Number of subjects: 20
Study 3554800 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruscus extract, trimethyl hesperidine chalcone and ascorbic acid (Phlebodril)
Number of subjects: 50
Study 3554800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30876827 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-fat diet (fat 40%, carbohydrate 46%, protein 14%)
Number of subjects: 3
Study 30876827 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-fat diet
Number of subjects: 3
Study 29957664 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Level Light Therapy (LLLT)
Number of subjects: 100
Study 29957664 — intervention group
Group type: COMPARATOR
Intervention: Sham light treatment
Number of subjects: 100
Study 27465740 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the clinical trial
Number of subjects: 76